FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1608409875> ?p ?o ?g. }

• W1608409875 endingPage "51" @default.
• W1608409875 startingPage "45" @default.
• W1608409875 abstract "Pre-clinical studies suggest that anti-angiogenic agents may be toxic to the developing growth plate. The purpose of this study was to evaluate the incidence of growth plate abnormalities in children with refractory cancer undergoing anti-angiogenic therapy.Targeted radiographic studies from 53 subjects enrolled on six separate Children's Oncology Group Phase 1 and Pilot Consortium clinical trials evaluating new anti-cancer agents interfering with angiogenesis were reviewed. Subjects received tyrosine kinase inhibitors with anti-angiogenic effects (n = 35), monoclonal antibodies targeting vascular endothelial growth factor (VEGF) (n = 13), or angiopoietin (n = 5). Radiographs of their distal femur/proximal tibia were obtained at baseline. Follow-up radiographs were obtained after odd-numbered treatment cycles in patients with open growth plates who did not experience disease progression prior to cycle 3.Baseline and follow-up growth plate radiographs were acquired in 48/53 (90%) of patients. Five patients (9.4%), all of whom received a specific VEGF/VEGFR blocking agent (sunitinib [n = 1] or pazopanib [n = 4]), had growth plate abnormalities. Four patients had growth plate widening that was apparent on at least two successive radiographs, but was not confirmed by MRI. The fifth patient had progressive growth plate widening and evidence of physeal cartilage hypertrophy on MRI. Subsequent off treatment radiographs showed that the growth plate changes were reversible.Growth plate abnormalities occur in a small, but relevant number of patients undergoing anti-angiogenic therapy. These results support the need for growth plate monitoring in children with open growth plates who are receiving anti-angiogenic therapy, and for improved methods to assess toxicity of anti-angiogenic agents to the developing skeleton." @default.
• W1608409875 created "2016-06-24" @default.
• W1608409875 creator A5001066329 @default.
• W1608409875 creator A5017501517 @default.
• W1608409875 creator A5027468886 @default.
• W1608409875 creator A5032126905 @default.
• W1608409875 creator A5041913264 @default.
• W1608409875 creator A5050571054 @default.
• W1608409875 creator A5059541221 @default.
• W1608409875 creator A5066484657 @default.
• W1608409875 creator A5071679104 @default.
• W1608409875 creator A5073659294 @default.
• W1608409875 creator A5083758349 @default.
• W1608409875 date "2014-09-24" @default.
• W1608409875 modified "2023-10-16" @default.
• W1608409875 title "Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: A report from the children's oncology group phase I consortium" @default.
• W1608409875 cites W1583699618 @default.
• W1608409875 cites W1839228463 @default.
• W1608409875 cites W1972139077 @default.
• W1608409875 cites W1976382591 @default.
• W1608409875 cites W1976893749 @default.
• W1608409875 cites W1979530999 @default.
• W1608409875 cites W1982426375 @default.
• W1608409875 cites W1985429138 @default.
• W1608409875 cites W1985804036 @default.
• W1608409875 cites W1996806798 @default.
• W1608409875 cites W2000292756 @default.
• W1608409875 cites W2004258351 @default.
• W1608409875 cites W2011802894 @default.
• W1608409875 cites W2019367530 @default.
• W1608409875 cites W2041808802 @default.
• W1608409875 cites W2046507292 @default.
• W1608409875 cites W2097060135 @default.
• W1608409875 cites W2109227311 @default.
• W1608409875 cites W2113749943 @default.
• W1608409875 cites W2117692326 @default.
• W1608409875 cites W2120304148 @default.
• W1608409875 cites W2122352690 @default.
• W1608409875 cites W2123467424 @default.
• W1608409875 cites W2124723876 @default.
• W1608409875 cites W2130548669 @default.
• W1608409875 cites W2142878985 @default.
• W1608409875 cites W2157706519 @default.
• W1608409875 cites W2158927044 @default.
• W1608409875 cites W2160133003 @default.
• W1608409875 cites W2161287425 @default.
• W1608409875 cites W2162216424 @default.
• W1608409875 cites W2396134644 @default.
• W1608409875 cites W2531276114 @default.
• W1608409875 cites W3140415961 @default.
• W1608409875 cites W59174886 @default.
• W1608409875 doi "https://doi.org/10.1002/pbc.25229" @default.
• W1608409875 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4237627" @default.
• W1608409875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25257751" @default.
• W1608409875 hasPublicationYear "2014" @default.
• W1608409875 type Work @default.
• W1608409875 sameAs 1608409875 @default.
• W1608409875 citedByCount "25" @default.
• W1608409875 countsByYear W16084098752015 @default.
• W1608409875 countsByYear W16084098752016 @default.
• W1608409875 countsByYear W16084098752017 @default.
• W1608409875 countsByYear W16084098752018 @default.
• W1608409875 countsByYear W16084098752020 @default.
• W1608409875 countsByYear W16084098752021 @default.
• W1608409875 countsByYear W16084098752022 @default.
• W1608409875 countsByYear W16084098752023 @default.
• W1608409875 crossrefType "journal-article" @default.
• W1608409875 hasAuthorship W1608409875A5001066329 @default.
• W1608409875 hasAuthorship W1608409875A5017501517 @default.
• W1608409875 hasAuthorship W1608409875A5027468886 @default.
• W1608409875 hasAuthorship W1608409875A5032126905 @default.
• W1608409875 hasAuthorship W1608409875A5041913264 @default.
• W1608409875 hasAuthorship W1608409875A5050571054 @default.
• W1608409875 hasAuthorship W1608409875A5059541221 @default.
• W1608409875 hasAuthorship W1608409875A5066484657 @default.
• W1608409875 hasAuthorship W1608409875A5071679104 @default.
• W1608409875 hasAuthorship W1608409875A5073659294 @default.
• W1608409875 hasAuthorship W1608409875A5083758349 @default.
• W1608409875 hasBestOaLocation W16084098752 @default.
• W1608409875 hasConcept C121608353 @default.
• W1608409875 hasConcept C126322002 @default.
• W1608409875 hasConcept C141071460 @default.
• W1608409875 hasConcept C143998085 @default.
• W1608409875 hasConcept C167734588 @default.
• W1608409875 hasConcept C2777025900 @default.
• W1608409875 hasConcept C2779490328 @default.
• W1608409875 hasConcept C2780394083 @default.
• W1608409875 hasConcept C71924100 @default.
• W1608409875 hasConceptScore W1608409875C121608353 @default.
• W1608409875 hasConceptScore W1608409875C126322002 @default.
• W1608409875 hasConceptScore W1608409875C141071460 @default.
• W1608409875 hasConceptScore W1608409875C143998085 @default.
• W1608409875 hasConceptScore W1608409875C167734588 @default.
• W1608409875 hasConceptScore W1608409875C2777025900 @default.
• W1608409875 hasConceptScore W1608409875C2779490328 @default.
• W1608409875 hasConceptScore W1608409875C2780394083 @default.
• W1608409875 hasConceptScore W1608409875C71924100 @default.
• W1608409875 hasIssue "1" @default.

• next